VitriVax, Inc.
VitriVax is a biotechnology company headquartered in Boulder, Colorado, dedicated to eliminating barriers to global vaccination through innovative vaccine formulation technologies. Their proprietary ALTA® platform enables thermostable, single-shot vaccines that can be transported and stored without refrigeration, potentially transforming vaccine delivery worldwide. The company collaborates with industry partners and has received multiple grants and contracts to develop advanced vaccine formulations for diseases such as HPV, rabies, polio, and COVID-19, aiming to improve global health and vaccine accessibility.
Industries
Nr. of Employees
small (1-50)
VitriVax, Inc.
5500 Central Avenue, Suite 220, Boulder Co 80301
Products
Thermostable, controlled-release vaccine formulation platform
A formulation approach combining spray-dried sugar-glass encapsulation with nanometer-scale metal-oxide coatings applied by atomic layer deposition to produce thermostable vaccine microparticles with timed antigen/adjuvant release for single-administration regimens.
Thermostable, controlled-release vaccine formulation platform
A formulation approach combining spray-dried sugar-glass encapsulation with nanometer-scale metal-oxide coatings applied by atomic layer deposition to produce thermostable vaccine microparticles with timed antigen/adjuvant release for single-administration regimens.
Services
Formulation services to convert vaccine candidates into thermostable, single-administration dosage forms using spray-drying, protective coatings, and controlled-release approaches for preclinical and clinical development.
Formulation services to convert vaccine candidates into thermostable, single-administration dosage forms using spray-drying, protective coatings, and controlled-release approaches for preclinical and clinical development.
Expertise Areas
- Vaccine formulation and stabilization
- Controlled-release vaccine delivery
- Thermostability testing and stability studies
- Preclinical vaccine development
Key Technologies
- Spray drying for microparticle and powder formulations
- Atomic layer deposition (ALD) coatings for microparticles
- Sugar-glass encapsulation
- Nanometer-thick metal-oxide protective coatings
News & Updates
Funding to develop thermostable HPV vaccines and pilot manufacturing capacity.
Contract to develop single-shot vaccines for melioidosis and glanders.
Funding to develop thermostable polio vaccines for future combination vaccines.
Presented a lightning talk on vaccine innovation at BARDA Industry Day 2020.
Ted Randolph named a giant by the Journal of Pharmaceutical Science for his contributions to biopharmaceutical formulation.
Funding to develop thermostable HPV vaccines and pilot manufacturing capacity.
Contract to develop single-shot vaccines for melioidosis and glanders.
Funding to develop thermostable polio vaccines for future combination vaccines.
Presented a lightning talk on vaccine innovation at BARDA Industry Day 2020.
Ted Randolph named a giant by the Journal of Pharmaceutical Science for his contributions to biopharmaceutical formulation.